ConductScience.org, home

Library / Trial comparisons

Prostate Screening vs Control: Prostate Cancer Deaths

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.004120.003530.00481wilsonClinicalTrials.gov
Risk in group 20.003780.003210.00445wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.00034-0.0005520.00123newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.090.871.36logClinicalTrials.gov
Odds ratio, group 1 over group 21.090.871.37logClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Prostate Screening than on Control2,940from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Prostate Screening
Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.
15838,340OG001ClinicalTrials.gov
Group 2ControlParticipants receive standard medical care.14538,345OG000ClinicalTrials.gov

Outcome 5

FieldValueSource
TypePRIMARYClinicalTrials.gov
TitleProstate Cancer DeathsClinicalTrials.gov
DescriptionProstate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.ClinicalTrials.gov
Time frameEvents through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.ClinicalTrials.gov
PopulationAll male participants randomized were analyzed. An intention-to-treat analysis was performed.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleScreening for Prostate Cancer in Older Patients (PLCO Screening Trial)ClinicalTrials.gov
NCT numberNCT00002540ClinicalTrials.gov
PhasesNAClinicalTrials.gov
ConditionsProstate CarcinomaClinicalTrials.gov
InterventionsLaboratory Biomarker Analysis, Medical Examination Assessment, Screening Questionnaire AdministrationClinicalTrials.gov
Lead sponsorNational Cancer Institute (NCI)ClinicalTrials.gov
Results first posted2014-06-26ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT00002540?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.